The Efficacy and Safty of Proton Pump Inhibitor (Lansoprazole)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 300 participants.

Also called NCT05820048

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 300 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05820048
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Not reported
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05820048. Randomized; single masking; primary purpose prevention. Start 2023-05-01 (anticipated); primary completion 2024-04-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
The Efficacy and Safty of Proton Pump Inhibitor (Lansoprazole)
Acronym
PPI
Intervention (Drug)
Lansoprazole 15 mg
Lead sponsor
Daejeon St. Mary's hospital (class: other)
Collaborator
Jeil Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct05820048
Content hash
efe1db7c47d7aca39e30602f3dd696fc3ddc6d29ec6da585346406e6a79ca4ba